Efficacy and Safety of Combination Androgen-Receptor Signaling Inhibitors, Denosumab, and Local Radiotherapy for...

Area of Science:

• Oncology
• Urology
• Medical Research

Background:

• Metastatic castration-sensitive prostate cancer (mCSPC) treatment has evolved with combination therapies.
• The efficacy of local radiation therapy (LRT) combined with denosumab chemotherapy is under investigation.
• Prostate cancer with multiple bone metastases (poly-PCa) requires effective treatment strategies.

Purpose of the Study:

• To provide an interim evaluation of a novel combination therapy for poly-PCa.
• The study assesses androgen receptor signaling inhibitors, denosumab, LRT, and metastasis-directed therapy (MDT).
• The goal is to improve oncological outcomes in patients with poly-PCa.

Main Methods:

• A single-arm prospective study is evaluating enzalutamide, LRT, denosumab, and MDT.
• The study focuses on patients with poly-PCa.
• Primary endpoints include prostate-specific antigen (PSA)-based progression-free survival (PFS) and radiographic PFS (rPFS).

Main Results:

• Twenty patients with poly-PCa were enrolled, with a median follow-up of 18.0 months.
• The 1-year PFS rate is 84.4%, and the radiographic PFS (rPFS) rate is 100%.
• 85.0% of patients achieved a ≥90% PSA reduction, and 50.0% maintained PSA levels <0.2 ng/mL.

Conclusions:

• The evaluated treatment strategy is expected to enhance oncological outcomes for poly-PCa patients.
• Interim results suggest significant efficacy in terms of PFS and PSA response.
• A comprehensive report with more patients and longer follow-up is forthcoming.